A new form of screening may improve survival rates among people with glioblastoma by helping to identify those most likely to benefit from certain types of Immunotherapy. – The Institute of Cancer Research
Quoting
“NEWS: A new form of screening may improve survival rates among people with glioblastoma brain tumours by helping to identify those most likely to benefit from certain types of Immunotherapy.
Innovative preclinical research has shown that a molecular imaging technique can reveal the presence of a protein called PD-L1 in glioblastomas – the most common type of cancerous brain tumor in adults.
Alongside other measures, tests to detect high levels of PD-L1 could help direct treatment decisions, potentially leading to better patient outcomes.
Dr. Gabriela Kramer-Marek, Group Leader in Preclinical Molecular Imaging at the ICR who led this preclinical work, said:
‘The treatment for glioblastoma has not changed for decades. Although we still do not have a cure, I believe that this new screening approach could definitely change patient outcomes.'”
For details click here.
Source: The Institute of Cancer Research/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023